The cardiac hyperpolarization-activated “funny” current (I_f), which contributes to sinoatrial node (SAN) pacemaking, has a more negative half-maximal activation voltage and smaller fully-activated macroscopic conductance in human than in rabbit SAN cells. The consequences of these differences for the relative roles of I_f in the two species, and for their responses to the specific bradycardic agent ivabradine at clinical doses have not been systematically explored. This study aims to address these issues, through incorporating rabbit and human I_f formulations developed by Fabbri et al. into the Severi et al. model of rabbit SAN cells. A theory was developed to correlate the effect of I_f reduction with the total inward depolarising current (I_total) during diastolic depolarization. Replacing the rabbit I_f formulation with the human one increased the pacemaking cycle length (CL) from 355 to 1,139 ms. With up to 20% I_f reduction (a level close to the inhibition of I_f by ivabradine at clinical concentrations), a modest increase (~5%) in the pacemaking CL was observed with the rabbit I_f formulation; however, the effect was doubled (~12.4%) for the human I_f formulation, even though the latter has smaller I_f density. When the action of acetylcholine (ACh, 0.1 nM) was considered, a 20% I_f reduction markedly increased the pacemaking CL by 37.5% (~27.3% reduction in the pacing rate), which is similar to the ivabradine effect at clinical concentrations. Theoretical analysis showed that the resultant increase of the pacemaking CL is inversely proportional to the magnitude of I_total during diastolic depolarization phase: a smaller I_f in the model resulted in a smaller I_total amplitude, resulting in a slower pacemaking rate; and the same reduction in I_f resulted in a more significant change of CL in the cell model with a smaller I_total. This explained the mechanism by which a low dose of ivabradine slows pacemaking rate more in humans than in the rabbit. Similar results were seen in the Fabbri et al. model of human SAN cells, suggesting our observations are model-independent. Collectively, the results of study explain why low dose ivabradine at clinically relevant concentrations acts as an effective bradycardic agent in modulating human SAN pacemaking.